Lexeo CFO granted RSUs and stock options

Lexeo Therapeutics, Inc.’s Chief Financial Officer Louis Edward Tamayo reported new equity awards.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc.’s Chief Financial Officer Louis Edward Tamayo reported new equity awards. On February 4, 2026, he received 44,665 shares of Common Stock as restricted stock units (RSUs) at $0 per share, bringing his directly owned Common Stock to 89,665 shares.

The RSUs vest over time: 25% on February 15, 2027, with the remaining RSUs vesting in 1/16th quarterly installments on the company’s standard vesting dates, subject to continued service. He was also granted a stock option to buy 226,665 shares of Common Stock at an exercise price of $7.27 per share, expiring on February 3, 2036. For this option, 25% of the underlying shares vest and become exercisable on February 4, 2027, with the rest vesting in 1/48th monthly installments, also subject to continuous service.

Insider Trade Summary

Grant/Award: 271,330 shares

Grant/Award 2 txns

Insider Tamayo Louis Edward

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	226,665	$0.00	$0.00
Grant/Award	Common Stock	44,665	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 226,665 contracts (Direct); Common Stock — 89,665 shares (Direct)

Footnotes (3)

1. F1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
2. F2. The reported securities are RSUs.
3. F3. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Lexeo Therapeutics (LXEO) CFO report on February 4, 2026?

Lexeo Therapeutics CFO Louis Edward Tamayo reported receiving 44,665 restricted stock units and a stock option for 226,665 shares on February 4, 2026. Both awards vest over several years and are contingent on his continued service with the company.

How many Lexeo Therapeutics (LXEO) shares does the CFO own after this Form 4 filing?

After the reported transaction, the CFO directly beneficially owns 89,665 shares of Lexeo Therapeutics Common Stock. This reflects the addition of 44,665 restricted stock units granted at no cost, subject to multi-year vesting conditions tied to continued employment.

What are the vesting terms for the Lexeo Therapeutics CFO’s RSU grant?

The CFO’s 44,665 RSUs vest 25% on February 15, 2027, with the remaining units vesting in 1/16th quarterly installments thereafter. Vesting occurs on Lexeo’s standard quarterly vesting dates and requires the CFO to remain in continuous service through each vesting date.

What stock option did the Lexeo Therapeutics (LXEO) CFO receive and at what exercise price?

The CFO received a stock option covering 226,665 shares of Lexeo Therapeutics Common Stock at an exercise price of $7.27 per share. The option was granted on February 4, 2026 and is scheduled to expire on February 3, 2036, if not earlier exercised.

How does the Lexeo Therapeutics CFO’s stock option vest over time?

For the stock option, 25% of the 226,665 underlying shares vest and become exercisable on February 4, 2027. The remaining shares vest in 1/48th monthly installments thereafter, conditioned on the CFO’s continuous service with Lexeo Therapeutics throughout the vesting period.

Are the Lexeo Therapeutics CFO’s reported RSUs and options subject to continued service?

Yes. Both the RSUs and stock option require the CFO’s ongoing service to vest. RSUs vest quarterly after an initial milestone, while the option vests partly on February 4, 2027, with the balance vesting monthly, all contingent on continuous employment with Lexeo.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tamayo Louis Edward

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		44,665(1)	A	$0	89,665(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.27	02/04/2026		A		226,665		(3)	02/03/2036	Common Stock	226,665	$0	226,665	D

Explanation of Responses:

1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

2. The reported securities are RSUs.

3. 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.